These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 1356683

  • 1. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ, McDermott BJ, Roberts SD.
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
    Taggart AJ, McDermott B, Delargy M, Elborn S, Forbes J, Roberts SD, Ahnfelt NO.
    Scand J Rheumatol Suppl; 1987 Oct; 64():29-36. PubMed ID: 2893450
    [Abstract] [Full Text] [Related]

  • 3. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G, Zylber-Katz E, Rachmilewitz D, Levy M.
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [Abstract] [Full Text] [Related]

  • 4. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ, Resetarits DE, Wilferth WW, Blumenthal HP, Bates TR.
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [Abstract] [Full Text] [Related]

  • 5. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
    Pullar T, Hunter JA, Capell HA.
    Ann Rheum Dis; 1985 Dec; 44(12):831-7. PubMed ID: 2867746
    [Abstract] [Full Text] [Related]

  • 6. History of enteric coated sulfasalazine in rheumatoid arthritis.
    Pinals RS.
    J Rheumatol Suppl; 1988 Sep; 16():1-4. PubMed ID: 2903922
    [Abstract] [Full Text] [Related]

  • 7. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
    Kuhn UD, Anschütz M, Schmücker K, Schug BS, Hippius M, Blume HH.
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
    [Abstract] [Full Text] [Related]

  • 8. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR, Blumenthal HP, Pieniaszek HJ.
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [Abstract] [Full Text] [Related]

  • 9. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD, Alpers DH, Keating JP.
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [Abstract] [Full Text] [Related]

  • 10. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment.
    Bax DE, Greaves MS, Amos RS.
    Br J Rheumatol; 1986 Aug; 25(3):282-4. PubMed ID: 2873862
    [Abstract] [Full Text] [Related]

  • 11. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
    Awni WM, Braeckman RA, Locke CS, Dubé LM, Granneman GR.
    Clin Pharmacokinet; 1995 Aug; 29 Suppl 2():98-104. PubMed ID: 8620678
    [Abstract] [Full Text] [Related]

  • 12. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.
    Coyle JD, Boudoulas H, Lima JJ.
    Biopharm Drug Dispos; 1991 Nov; 12(8):599-612. PubMed ID: 1724922
    [Abstract] [Full Text] [Related]

  • 13. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF, George D, Milsap RL, Pogonowska-Wala E, Owerbach J, Lebenthal E, Jusko WJ.
    Pediatr Pharmacol (New York); 1982 Nov; 2(4):323-33. PubMed ID: 6152489
    [Abstract] [Full Text] [Related]

  • 14. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
    Das KM, Eastwood MA, McManus JP, Sircus W.
    Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
    [Abstract] [Full Text] [Related]

  • 15. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME, Wallace SM, Hindmarsh KW, Brown MA.
    Eur J Clin Pharmacol; 1981 Aug; 21(3):243-50. PubMed ID: 6119205
    [No Abstract] [Full Text] [Related]

  • 16. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR, Blumenthal HP, Pieniaszek HJ.
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
    Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre MS, Broly F, Piette F, Bergoend H.
    Ann Dermatol Venereol; 1997 Sep; 124(2):151-6. PubMed ID: 9740825
    [Abstract] [Full Text] [Related]

  • 18. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM, Eastwood MA.
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [Abstract] [Full Text] [Related]

  • 19. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ, Giehler B, Lohmann D, Schiedewitz W.
    Gastroenterol J; 1990 Nov; 49(4):160-4. PubMed ID: 1970478
    [Abstract] [Full Text] [Related]

  • 20. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis.
    Kitas GD, Farr M, Waterhouse L, Bacon PA.
    Scand J Rheumatol; 1992 Nov; 21(5):220-5. PubMed ID: 1359635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.